Global Cholera Vaccines Market 2018-2022

Detailed TOC of Global Cholera Vaccines Market 2018-2022

Table of Contents
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
• Market outline
PART 05: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 06: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 08: PIPELINE LANDSCAPE
PART 09: MARKET SEGMENTATION BY PRODUCT
• Overview
• Comparison by product
• Shanchol
• DUKORAL
• Vaxchora
• Market opportunity by product
PART 10: SEGMENTATION BY GEOGRAPHY
• Overview
• Regional comparison
• Americas
• EMEA
• APAC
• Key leading countries
• Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
• Market challenges
PART 13: MARKET TRENDS
• Increasing number of public-private initiatives
• Focus on developing countries
PART 14: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive landscape
PART 15: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• PaxVax
• Sanofi
• Valneva
PART 16: APPENDIX
• List of abbreviations
List of Exhibits 
Exhibit 01: Cholera: Overview
Exhibit 02: Severe form of cholera
Exhibit 03: Major cholera outbreaks 2010-2017
Exhibit 04: Parent market
Exhibit 05: Market characteristics
Exhibit 06: Global cholera vaccines market: Segmentation
Exhibit 07: Market definition: Inclusions and exclusions checklist
Exhibit 08: Market size 2017
Exhibit 09: Validation techniques employed for market sizing 2017
Exhibit 10: Global cholera vaccines market 2017-2022 ($ millions)
Exhibit 11: Global cholera vaccines market: Year-over-year growth 2018-2022 (%)
Exhibit 12: Five forces analysis 2017
Exhibit 13: Five forces analysis 2022
Exhibit 14: Bargaining power of buyers
Exhibit 15: Bargaining power of suppliers
Exhibit 16: Threat of new entrants
Exhibit 17: Threat of substitutes
Exhibit 18: Threat of rivalry
Exhibit 19: Market condition 2017
Exhibit 20: Pipeline landscape by sponsors or collaborators
Exhibit 21: Key clinical trials
Exhibit 22: Global cholera vaccines market: Segmentation by product 2017-2022 (% share)
Exhibit 23: Comparison by product
Exhibit 24: Description of Shanchol
Exhibit 25: Global Shanchol market 2017-2022 ($ millions)
Exhibit 26: Global Shanchol market: Year-over-year growth 2018-2022 (%)
Exhibit 27: Description of DUKORAL
Exhibit 28: Global DUKORAL market 2017-2022 ($ millions)
Exhibit 29: Global DUKORAL market: Year-over-year growth 2018-2022 (%)
Exhibit 30: Global Vaxchora market 2017-2022 ($ millions)
Exhibit 31: Global Vaxchora market: Year-over-year growth 2018-2022 (%)
Exhibit 32: Market opportunity by product
Exhibit 33: Global cholera vaccines market: Segmentation by geography 2017-2022 (% share)
Exhibit 34: Regional comparison
Exhibit 35: Cholera vaccines market in Americas 2017-2022 ($ millions)
Exhibit 36: Cholera vaccines market in Americas: Year-over-year growth 2018-2022 (%)
Exhibit 37: Cholera vaccines market 2017-2022 ($ millions)
Exhibit 38: Cholera vaccines market in EMEA: Year-over-year growth 2018-2022 (%)
Exhibit 39: Cholera vaccines market in APAC 2017-2022 ($ millions)
Exhibit 40: Cholera vaccines market in APAC: Year-over-year growth 2018-2022 (%)
Exhibit 41: Key leading countries: Prevalence of cholera
Exhibit 42: Market opportunity
Exhibit 43: Countries with high proportion of population without sanitation 2014
Exhibit 44: Number of departures from US to Asia 2012-2015
Exhibit 45: Departures to top Asian countries from US 2015
Exhibit 46: Initiatives to prevent and manage cholera
Exhibit 47: Vendor landscape
Exhibit 48: Landscape disruption
Exhibit 49: Competitive structure analysis
Exhibit 50: Vendors covered
Exhibit 51: Vendor classification
Exhibit 52: Market positioning of vendors
Exhibit 53: PaxVax: Overview
Exhibit 54: PaxVax: Business segments
Exhibit 55: PaxVax: Organizational developments
Exhibit 56: PaxVax: Geographic focus
Exhibit 57: PaxVax: Segment focus
Exhibit 58: PaxVax: Key offerings
Exhibit 59: PaxVax: Key customers
Exhibit 60: Sanofi: Overview
Exhibit 61: Sanofi: Business segments
Exhibit 62: Sanofi: Organizational developments
Exhibit 63: Sanofi: Geographic focus
Exhibit 64: Sanofi: Segment focus
Exhibit 65: Sanofi: Key offerings
Exhibit 66: Sanofi: Key customers
Exhibit 67: Valneva: Overview
Exhibit 68: Valneva: Business segments
Exhibit 69: Valneva: Organizational developments
Exhibit 70: Valneva: Geographic focus
Exhibit 71: Valneva: Segment focus
Exhibit 72: Valneva: Key offerings
Exhibit 73: Valneva: Key customers